Surveillance for hepatocellular carcinoma: In whom and how?

Therapeutic Advances in Gastroenterology

Volumn 4, Issue 1, 2011, Pages 5-10

  Serag, Hashem B ^a   Davila, Jessica A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; LECTIN;

ALCOHOL LIVER DISEASE; CANCER SURGERY; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SURVEILLANCE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT; MORTALITY; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; ULTRASOUND;

EID: 80052348326     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X10385964     Document Type: Editorial

References (36)

1. Arguedas M.R. Chen V.K. Eloubeidi M.A. Fallon M.B. (2003) Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost–utility analysis. Am J Gastroenterol 98: 679–690.
2. Bayati N. Silverman A.L. Gordon S.C. (1998) Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol 93: 2452–2456.
3. Bruix J. Sherman M. Llovet J.M. Beaugrand M. Lencioni R. Burroughs A.K. et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421–430.
4. Carr B.I. Kanke F. Wise M. Satomura S. (2007) Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 52: 776–782.
5. Chen J.G. Parkin D.M. Chen Q.G. Lu J.H. Shen Q.J. Zhang B.C. et al (2003) Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 10: 204–209.
6. Davila, J.A., Henderson, L.M., Kramer, J.R., Richardson, P., Duan, Z., Kanwal, F. et al. (2010 a) Utilization of Surveillance for Hepatocellular Carcinoma among HCV-infected Veterans in the United States. in press.
7. Davila J.A. Morgan R.O. Richardson P.A. Du X.L. McGlynn K.A. El-Serag H.B. (2010 b) Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 52: 132–141.
8. Davila J.A. Weston A. Smalley W. El Serag H.B. (2007) Utilization of screening for hepatocellular carcinoma in the United States. J Clin Gastroenterol 41: 777–782.
9. Durazo F.A. Blatt L.M. Corey W.G. Lin J.H. Han S. Saab S. et al (2008) Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 23: 1541–1548.
10. Ebara M. Ohto M. Kondo F. (1989) Strategy for early diagnosis of hepatocellular carcinoma (HCC). Ann Acad Med Singapore 18: 83–89.
11. El Serag H.B. (2002) Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36: S74–S83.
12. El Serag H.B. Siegel A.B. Davila J.A. Shaib Y.H. Cayton-Woody M. McBride R. et al (2006) Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 44: 158–166.
13. El-Serag H.B. Rudolph K.L. (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557–2576.
14. Fattovich G. Stroffolini T. Zagni I. Donato F. (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127: S35–S50.
15. Franca A.V. Elias J.J. Lima B.L. Martinelli A.L. Carrilho F.J. (2004) Diagnosis, staging and treatment of hepatocellular carcinoma. Braz J Med Biol Res 37: 1689–1705.
16. Kobayashi K. Sugimoto T. Makino H. Kumagai M. Unoura M. Tanaka N. et al (1985) Screening methods for early detection of hepatocellular carcinoma. Hepatology 5: 1100–1105.
17. Kubota K. Ina H. Okada Y. Irie T. (2003) Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography. Dig Dis Sci 48: 581–586.
18. Leykum L.K. El Serag H.B. Cornell J. Papadopoulos K.P. (2007) Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol 5: 508–512.
19. Lin O.S. Keeffe E.B. Sanders G.D. Owens D.K. (2004) Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 19: 1159–1172.
20. Marrero J.A. Feng Z. Wang Y. Nguyen M.H. Befeler A.S. Roberts L.R. et al (2009) Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137: 110–118.
21. McMahon B.J. Bulkow L. Harpster A. Snowball M. Lanier A. Sacco F. et al (2000) Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 32: 842–846.
22. Okada S. Okazaki N. Nose H. Aoki K. Kawano N. Yamamoto J. et al (1993) Follow-up examination schedule of postoperative HCC patients based on tumor volume doubling time. Hepatogastroenterology 40: 311–315.
23. Patel D. Terrault N.A. Yao F.Y. Bass N.M. Ladabaum U. (2005) Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 3: 75–84.
24. Paul S.B. Gulati M.S. Sreenivas V. Madan K. Gupta A.K. Mukhopadhyay S. et al (2007) Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein. Oncology 72(Suppl. 1): 117–123.
25. Sheu J.C. Sung J.L. Chen D.S. Lai M.Y. Wang T.H. Yu J.Y. et al (1985) Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study. Cancer 56: 660–666.
26. Shimizu A. Shiraki K. Ito T. Sugimoto K. Sakai T. Ohmori S. et al (2002) Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis. Int J Mol Med 9: 245–250.
27. Singal A. Volk M.L. Waljee A. Salgia R. Higgins P. Rogers M.A. et al (2009) Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 30: 37–47.
28. Tong M.J. Blatt L.M. Kao V.W. (2001) Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol 16: 553–559.
29. Torzilli G. Minagawa M. Takayama T. Inoue K. Hui A.M. Kubota K. et al (1999) Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 30: 889–893.
30. Trevisani F. Cantarini M.C. Labate A.M. de Notariis S. Rapaccini G. Farinati F. et al (2004) Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol 99: 1470–1476.
31. Trevisani F. De N.S. Rapaccini G. Farinati F. Benvegnu L. Zoli M. et al (2002) Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 97: 734–744.
32. Wong L.L. Limm W.M. Severino R. Wong L.M. (2000) Improved survival with screening for hepatocellular carcinoma. Liver Transpl 6: 320–325.
33. Yoshino M. (1983) Growth kinetics of hepatocellular carcinoma. Jpn J Clin Oncol 13: 45–52.
34. Yu E.W. Chie W.C. Chen T.H. (2004) Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients? Cancer J 10: 317–325.
35. Yuen M.F. Cheng C.C. Lauder I.J. Lam S.K. Ooi C.G. Lai C.L. (2000) Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 31: 330–335.
36. Zhang B.H. Yang B.H. Tang Z.Y. (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130: 417–422.